https://www.thebodypro.com/category/lamivudine-epivir-3tc/tag/conference-coverage
Lamivudine (3TC, Epivir)

Conference Coverage

The Latest

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy Img

M184V Mutation Associated With Increased Risk of Viral Blip but Not Viral Failure With 3TC-Based Dual Therapy

A retrospective analysis presented at CROI 2018 looked at risk of viral rebound in people who switched to lamivudine (Epivir, 3TC)-based dual antiretroviral therapy.

Promo Image

Long-Acting HIV Treatment: 5 Myths and Realities

Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? Researcher Charles W. Flexner recently addressed several common myths.

Promo Image

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy Img

Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy

A recent study revealed a surprising result: For the first time ever, an HIV treatment regimen consisting of two drugs was found to work just as well as a three-drug regimen.